Methodological considerations in cost of illness studies on Alzheimer disease.

Abstract : ABSTRACT: Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify which dimension had to be improved from a methodological perspective. First, we described the key points of cost study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of the different methods used. The methodological choices of the studies were analysed using an analytical grid which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the studies, annual total costs per patient vary from $2,935 to $52, 954. The methods, data sources, and estimated cost categories in each study varied widely. The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility, closer agreement among researchers on the methodological principles of cost studies would be desirable.
Type de document :
Article dans une revue
Health Economics Review, 2012, 2 (1), pp.18. 〈10.1186/2191-1991-2-18〉
Liste complète des métadonnées

Littérature citée [50 références]  Voir  Masquer  Télécharger
Contributeur : Ed. Bmc <>
Soumis le : lundi 4 février 2013 - 21:07:46
Dernière modification le : samedi 29 septembre 2018 - 09:52:02
Document(s) archivé(s) le : lundi 17 juin 2013 - 19:10:16


Fichiers éditeurs autorisés sur une archive ouverte




Nagede Costa, Helene Derumeaux, Thomas Rapp, Valérie Garnault, Laura Ferlicoq, et al.. Methodological considerations in cost of illness studies on Alzheimer disease.. Health Economics Review, 2012, 2 (1), pp.18. 〈10.1186/2191-1991-2-18〉. 〈inserm-00784893〉



Consultations de la notice


Téléchargements de fichiers